Competitive Insights & Strategic Opportunity Mapping

The Work

There is a meaningful difference between a competitive scan and a strategic opportunity map. A scan produces a table of competitors, what they sell, and where they are positioned. A map identifies where the real white space sits — not just empty positioning, but defensible positioning that the category can actually grow into. The two artifacts look superficially similar. The decisions they support are very different.

Most innovation prioritization exercises overweight what's loud. The benefit area with the most consumer chatter, the ingredient with the most influencer support, the category with the most recent product launches — these are easy to point at, and they generate consensus inside an organization. What they often miss is whether the position is defensible: whether claims will hold, whether the evidence base supports the story, whether regulatory frameworks will allow the message, and whether the supply chain can be protected.

RGM brings regulatory and evidence context into the opportunity map directly. A white space that requires claims the FDA has previously rejected is not a white space. A category that looks open but is structurally constrained by ingredient supply or by emerging regulatory action is not a real opportunity. Conversely, an under-noticed adjacency with strong scientific support and defensible claims may be worth more than the loud space everyone is already chasing.

The categories most regularly assessed in this work are supplements, women's health, longevity, gut health, skin health, and postbiotics — spaces where consumer momentum, scientific evolution, and competitive activity are all moving at once, and where prioritization decisions are being made under real time pressure.